OncoMatch/Clinical Trials/CNS Lymphoma (PCNSL)
CNS Lymphoma (PCNSL) Clinical Trials
OncoMatch filters CNS Lymphoma (PCNSL) trials by the molecular markers that determine eligibility — MYD88, CD79B, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout CNS Lymphoma (PCNSL) trials
Primary CNS lymphoma (PCNSL) is a rare, aggressive lymphoma confined to the central nervous system. MYD88 L265P and CD79B mutations together characterize the activated B-cell-like (ABC) DLBCL subtype that dominates PCNSL, with both mutations driving BTK pathway activation. This molecular dependency underlies the activity of BTK inhibitors in PCNSL.
Trial selection in PCNSL depends on disease state and prior high-dose methotrexate (HD-MTX) exposure. Front-line trials test variations on HD-MTX-based induction (R-MPV, MATRix-style regimens) and consolidation strategies (autologous stem cell transplant vs whole brain radiation, with autoSCT increasingly preferred to spare neurocognitive function). R/R trials test BTK inhibitors (which exploit the MYD88 / CD79B-driven BTK dependency), immunomodulatory drugs (lenalidomide), and novel combinations including bispecific antibodies. Elderly PCNSL trials (often patients >70) test de-intensified HD-MTX or non-MTX regimens for patients who can't tolerate full-dose induction.
PCNSL trial screening typically checks performance status, prior HD-MTX, and renal function. Performance status, often by Karnofsky for CNS-related fitness assessment, is foundational. Prior HD-MTX exposure (and number of cycles) defines whether front-line or post-induction trials apply. Prior autologous stem cell transplant status for consolidation or salvage trials. Prior BTK inhibitor exposure for R/R trials. Renal function (creatinine clearance) is screened on most trials because HD-MTX requires intact renal clearance. HIV status and immune competence for HIV-associated PCNSL trials.
Top recruiting CNS Lymphoma (PCNSL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
University of Rochester
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Hoffmann-La Roche
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
Sherief Abd-Elsalam
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
SecuraBio
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK
How OncoMatch finds CNS Lymphoma (PCNSL) trials for you
AI reads the protocol
Every CNS Lymphoma (PCNSL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select CNS Lymphoma (PCNSL) and mark your biomarker results — MYD88, CD79B — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.